08:00 - 08:30 REGISTRATION AND WELCOME

08:30 - 09:15 TNM Staging Session
Chairs:

What we learned with TNM 9 and what we expect to learn with TNM10?
Nodal dissection: What should surgeons do?
The ITMIG-IASLC nodal map
Q&A, Discussion 

09:15 - 10:00 Recent ITMIG Milestones
Chairs:

ITMIG Standards and Definitions
ITMIG Pathology Guidelines
ITMIG Survey on Clinical and Pathology Practice of the Diagnosis and Treatment of Thymic Epithelial Tumors
Q&A, Discussion  

10:00 - 11:00 Oral Abstract Session 1
Chairs:

6 ABSTRACTS PRESENTATIONS 

11:00 - 11:30 Coffee Break

Poster presentations 

11:30 - 12:15 ITMIG-TYME Joint Session
Chairs:

Italian network TYME
TETs Italian Registry
ITMIG collaboration with national networks and future directions
Q&A, Discussion  

12:15 - 13:00 Case Presentation with Audience Participation
Non-Oncologic Surgical Case
Chairs: 

Presentation with clinical, radiological and pathological comments
Q/A, Discussion

13:00 - 13:45 LUNCH BREAK

13:45 - 14:45 Management of Recurrent and Re-recurrent Disease
Chairs:

CASE PRESENTATION
Recurrence and primary TETs: is it the same disease?
Innovative therapies in thymic tumors and recurrences
Round table/audience discussion
The ITMIG recurrence classification: validation and possible updates  

14:45 - 15:45 Anti-angiogenesis, Immunotherapy and Novel Therapies in Thymic Carcinoma
Chairs:

The immunotherapy landscape: from clinical trials to clinical practice
Anti-angiogenics and combinations 
New treatment strategies: from immunohistochemistry to drug development (Antibody Drug Conjugates and bispecific)
Platinum based chemotherapy: still the best option?
Q&A, Discussion 

15:45 - 16:15 Coffee break

Poster presentations 

16:15 - 17:15 Neoadjuvant therapies: When, how and why
Chairs: 

What surgeons want to know on imaging in advanced thymic epithelial tumors? 
Potential neoadjuvant use of IO and targeted therapy in 2025 
Surgical challenges after neoadjuvant therapy
How to assess pathologic response after neoadjuvant therapy
Q&A, Discussion 

17:15 - 18:15 Nuclear Medicine and Interventional Radiology in TETs - a tailored approach
Chairs:

Prognostic value and role of FDG-PET-CT: Initial staging and after therapy – recommendations
Beyond FDG
Percutaneous ablation therapy in isolated or multiple extra-mediastinal lesions: is it worthwhile?
How to manage difficult cases?
Q&A, Discussion

19:00 - 20:00 WELCOME RECEPTION